Risk factors leading to glaucoma surgery of glaucoma patient using Japanese nationwide administrative claims data: A retrospective non-interventional cohort study

Chikako Shirai
Tohoku Daigaku Daigakuin Igaku Kei Kenkyuka Igakubu

Satoru Tsuda
Tohoku Daigaku Daigakuin Igaku Kei Kenkyuka Igakubu

Kunio Tarasawa
Tohoku Daigaku Daigakuin Igaku Kei Kenkyuka Igakubu

Kiyohide Fushimi
Tokyo Medical and Dental University: Tokyo Ika Shika Daigaku

Kenji Fujimori
Tohoku Daigaku Daigakuin Igaku Kei Kenkyuka Igakubu

Toru Nakazawa (ntoru@oph.med.tohoku.ac.jp)
Tohoku University Graduate School of Medicine https://orcid.org/0000-0002-5591-4155

Research article

Keywords: glaucoma, comorbidity, concomitant, administrative claims data, diagnosis procedure combination (DPC)

DOI: https://doi.org/10.21203/rs.3.rs-121909/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

Early recognition and management of baseline risk factors may play an important role in reducing glaucoma surgery burdens. However, no studies have investigated them using real-world data in Japan or other countries. This study aimed to clarify the risk factors leading to glaucoma surgery of glaucoma patient using the Japanese nationwide administrative claims data associated with the diagnosis procedure combination (DPC) system.

Methods

It was a retrospective, non-interventional cohort study. Data were collected from patients who were admitted to DPC participating hospitals, nationwide acute care hospitals and diagnosed with glaucoma between 2012 to 2018. The primary outcome was the risk factors associated with glaucoma surgery. The association between baseline characteristics and glaucoma surgery was identified using multivariable logistic regression analysis by comparing patients with and without glaucoma surgery. Meanwhile, the secondary outcomes included the rate of comorbidities, the rate of concomitant drug use and the treatment patterns of glaucoma eye drops at the index admission. Among patients with glaucoma surgery, the risk factors leading to cataract surgery were also evaluated as subgroup analysis.

Results

A total of 29,599 patients included in the analysis, 12,038 and 17,561 patients were in the glaucoma surgery and non-glaucoma surgery cohorts, respectively. The factors associated with the increase in glaucoma surgery were having allergies, taking concomitant drugs including cancer, depression, ischemic heart disease and peptic ulcer, being diagnosed with primary open-angle glaucoma and longer length of stay in hospital. In contrast, the factors associated with the decrease in glaucoma surgery were having hypertension, taking hypertension drug, age $\geq 80$ and female.

Conclusions

Special focus on Japanese patients with glaucoma who have allergy-related comorbidities or take immune, nervous, circulatory or gastrointestinal system-related concomitant drugs seems to be desirable.

Background

Glaucoma is a chronic progressive optic neuropathy that can lead to irreversible blindness, affecting over 70 million adults worldwide. Intraocular pressure (IOP)-lowering therapy is the only effective strategy recognized to date.$^{1-5}$
In Japan, glaucoma is the most common causes of blindness, accounting for 28.6% of all blind regression.\(^6\) It has an estimated prevalence of 5% in those aged over 40 years, that is, four million glaucoma patients.\(^7\) Owing to the aging Japanese population, and glaucoma increases with age,\(^8\),\(^9\) the future clinical and economic burden to the healthcare system is expected to increase.

Current therapies used to lower IOP are drug treatment (usually eye drops), laser treatment, surgical treatment, or a combination of these treatments are used.\(^5\) Surgical treatment is considered the final step in lowering IOP due to the improvement of drug treatment, and thus, patients with glaucoma undergoing surgical treatment represent severe or drug treatment resistance. Nevertheless, glaucoma surgery has incrementally advanced over the years. The search for safer and less invasive surgeries has been continued with emphasis on newer devices and techniques that use small incisions, a category described as micro-invasive glaucoma surgery.\(^10\)–\(^12\) New procedures for surgical treatment, however, have their own risks and complications, some of which might be unknown until long-term data become available.

Besides, to the best of our knowledge, there have been no published study results analyzing what background of patients with glaucoma who are receiving surgical treatment in routine clinical practice. Therefore, such study, in particular an analysis of the glaucoma treatment using a large-scale administrative database, is resulted in an important and useful information that reflects the current status of treatment and identifies issues to be considered.

The aim of this study was to clarify the risk factors leading to glaucoma surgery of glaucoma patients using the Japanese nationwide administrative claims data associated with the diagnosis procedure combination (DPC) system.\(^13\),\(^14\) In addition, the rate of comorbidities, the rate of concomitant drug use, and the treatment patterns of glaucoma eye drops at the index admission in patients with and without glaucoma surgery were also explored.

### Methods

#### Study design

This was a retrospective non-interventional cohort study using 6-year data (between 1 April 2012 and 31 March 2018) from the Japanese nationwide administrative claims data associated with the DPC system to identify the risk factors leading to glaucoma surgery of patients with glaucoma in Japan. Moreover, because glaucoma and cataract are leading causes of blindness worldwide and their co-existence is common in elderly people, the subgroup analysis was performed in patients with combined glaucoma and cataract surgery.

This study was registered with UMIN Clinical Trials (UMIN000037878). It was approved by the research ethics committee of the Tohoku University Graduate School of Medicine, Japan (No. 2019-1-897) and conducted in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving human. Because this study was based on secondary analysis of DPC
data that had already been anonymized unlikable, written informed consent from patients was not required.

**Data source and study cohort**

The DPC is a national administrative database of a case-mix classification system for acute inpatient care developed in Japan. Details of the system have been described elsewhere.\(^\text{15,16}\) The system was launched in 2003 among 82 special functional hospitals, with a rapidly increasing number of hospitals having adopted the system, which recently includes approximately 7 million inpatients per year from more than 1,000 hospitals, covering approximately 90% of all hospitalization to acute care hospital in Japan. The DPC data include administrative claims data and some clinical data. The DPC database includes data on the following elements: patient demographics (e.g., age and gender); primary diagnosis; comorbidities at admission; complications after admission; procedures including surgery, medication and devices used during hospitalization; length of stay; discharge status; and medical expenses.\(^\text{17–19}\) The primary diagnosis is limited to one. In order to optimize the accuracy of the recorded diagnoses, the responsible physicians are required to record the diagnoses disease name in the medical charts. A wide variety of centers, including academic, urban and rural hospitals, use the DPC system.\(^\text{20}\) These data were coded in the 10th revision of the International Statistical Classification of Disease (ICD10) and also the original Japanese code determined by the Ministry of Health, Labor and Welfare of Japan.

For this study, patients were extracted from the DPC data using SQL Server 2014 Management Studio (Microsoft Corporation). Eligible patients were those who were admitted to DPC participating hospitals, that is, nationwide acute care hospitals in Japan and diagnosed with glaucoma. Patients with glaucoma as the disease associated with the highest medical costs were identified based on the following ICD10 codes: H401 (normal tension glaucoma, primary open-angle glaucoma and open-angle glaucoma) and H409 (unspecified glaucoma) from 1 April 2012 to 31 March 2018 (study period). Figure 1 shows the patient selection process.

Glaucoma surgery (GS) was defined as the following claim code for medical procedure: 150335910 (trabeculectomy, TRAB). The trabeculotomy (TLO) is often additionally used during cataract surgery, while TRAB is more effective in lowering IOP than TLO and suitable for treating severe glaucoma patients, but highly invasive and rarely used for an additional surgery. To obtain an appropriate outcome of this study, we selected only TRAB as GS. The patients with glaucoma who had ≥ 2 records of GS, readmission to the DPC hospitals, < 12 months post-index continuous enrollment, in-hospital death or missing data during the study period were excluded, and furthermore, this study used the strict inclusion criteria that excluded data for the first and last year during the study period. The patients with only 1 record of GS from 1 April 2013 to 31 March 2017 was defined as the newly undergone GS (patients with GS [GS cohort]).

On the other hand, patients who had not undergone GS (patients without GS [non-GS cohort]) were defined as those who had no record of GS during the study period and who had no record of GS from 1 April 2013 to 31 March 2017. Patients with a history of other GS, such as the following claim code for
medical procedure: 150088410 (trabeculotomy, TLO) was also excluded. Furthermore, to maintain the independence of observation and to exclude readmission to hospital, only the data associated with the last admission (index admission) from 1 April 2013 to 31 March 2017 were used as the data of the patients without GS.

Among the patients with GS, those who have undergone cataract surgery (CS) were defined as patients with CS (CS cohort). CS was defined as the following claim code for medical procedure: 150253010, 190179210, 190195910 (all 3 codes related to lens reconstruction). On the other hand, persons who had not undergone CS were defined as patients without CS (non-CS cohort).

**Variables**

Variable used in this study included age, gender, body mass index (BMI), smoking index, season at admission, length of stay in hospital (LOS), Charlson comorbidity index (CCI), comorbidities at index admission (17 disease as the possible risk factors for glaucoma: hypertension, hypotension, ischemic heart disease, heart failure, stroke, diabetes, hyperlipidemia, electrolyte disorders, thyroid dysfunction, systemic lupus erythematosus, dementia, depression, mental disorders, cancer, allergies, peptic ulcer and liver insufficiency/failure), concomitant drugs at index admission (systemic oral drugs for the 17 disease listed above) and glaucoma related measure including glaucoma types, topical glaucoma drugs at index admission (see Table 1 for medical and pharmacy codes). Topical glaucoma treatments included prostaglandin analog (PG), β blocker (BB), carbonic anhydrase inhibitor (CAI), α2 agonist (AA), α1 blocker (AB), αβ blocker (ABB), sympathomimetics, rho-associated coiled kinase inhibitor (ROCKI), fixed-combinations and their generics. Patients were categorized into 6 age groups: ≤39, 40–49, 50–59, 60–69, 70–79, ≥80; two gender groups: male, female; four BMI groups: thin (<18.5), normal (≥18.5 < 25), fat (≥25), not classified; four season groups: spring (April-June), summer (July-September), autumn (October-December), winter (January - March); 4 CCI groups: low (0), medium (1–2), high (3–4), very high (≥5) cases.
| Therapeutic Category | ICD-10 codes | Drug codes* | Drug generic name |
|----------------------|--------------|-------------|-------------------|
| Hypertension         | I10          | 213, 214, 217 |                  |
| Hypotension          | I95%         | 216         |                  |
| Ischemic heart disease | I20%-I25%  | 212, 214, 217 |                  |
| Heart failure        | I50%         | 211, 213, 214, 217 | |
| Stroke               | I63%         | 333, 339    |                  |
| Diabetes             | E10%-E14%   | 396         |                  |
| Hyperlipidemia       | E78%         | 218         |                  |
| Electrolyte disorders | E87%       | 321, 322    |                  |
| Thyroid dysfunction  | E02%, E03%  | 243         |                  |
| Systemic lupus erythematous | M32%      | 2456001, 3999005, 3999038 | Prednisolone, Azathioprine, Hydroxychloroquine |
| Depression           | F251, F31%-F35% | 1179      |                  |
| Dementia             | F00%-F03%   | 1190012, 1190018, 1190019, 1190770 | Donepezil, Memantine, Galantamine, Rivastigmine |
| Mental disorders     | F09, F23, F28, F29 | 117      |                  |
| Cancer               | C00%-C97%   | 421, 422, 423, 424, 429 | |
| Allergies            | D690, D721, H011, H016, H169, H200, H065, H651, H654, H659, J301-J304, L23%, L500, T781, T784 | 441, 442, 443, 449 | |
| Peptic ulcer         | F54, K221, K25%, K26%, K27%, K28%, K51%, K626, K633, K828, K838 | 232 | |

ICD-10, international classification of disease; NTG, normal tension glaucoma; OAG, open angle glaucoma; POAG, primary open angle glaucoma

* Classified by the Drug Therapeutic Class Code in Japan

** Furthermore, commonly prescribed glaucoma eye drops were narrowed down by the Japanese National Health Insurance drug price listing pharmaceuticals code
| Therapeutic Category | ICD-10 codes | Drug codes* | Drug generic name |
|----------------------|--------------|-------------|------------------|
| Liver insufficiency/failure | K70%-K77% | 625, 6399, 3919, 3999 | |
| Glaucoma (NTG/POAG/OAG) | H401 | 131 ** | |
| Unspecified glaucoma | H409 | 131 ** | |

ICD-10, international classification of disease; NTG, normal tension glaucoma; OAG, open angle glaucoma; POAG, primary open angle glaucoma

* Classified by the Drug Therapeutic Class Code in Japan

** Furthermore, commonly prescribed glaucoma eye drops were narrowed down by the Japanese National Health Insurance drug price listing pharmaceuticals code

**Study outcomes**

The primary outcome was the risk factors associated with GS using patients’ baseline demographic and clinical characteristics at the index admission. The secondary outcomes were the rate of comorbidities, the rate of concomitant use of prescribed systemic oral drugs and the treatment patterns of prescribed topical glaucoma drugs (eye drops) at the index admission in the GS and non-GS cohorts. Furthermore, GS cohort was divided into two cohorts based on with or without CS. The primary and secondary outcomes were also performed.

**Statistical analysis**

Descriptive analysis was performed for the basic features of the data as in mean with standard deviation (SD) for continuous variables and frequency (n) and percentage (%) for categorical variables. For outcomes, the difference between the GS and non-GS cohorts were compared according to baseline characteristics. Based on variable types and normality, the Chi-square test (or Fisher’s exact test, if cell expectations were less than 5), the Student’s t-test and the Mann-Whitney U test were used to examine differences.

To identify the factors associated with GS, logistic regression analysis was used. Potentially significant variables on univariable analysis (p < 0.05) were considered a priori for inclusion in a multivariable logistic regression model. Pairwise correlation coefficients were examined between variables that were potentially related before inclusion in our multivariable model to avoid collinearity. Stepwise forward-backward elimination analysis was performed and variables with p < 0.0001 were retained in the final multivariable model. In order to validate the final model, the variance inflation factor (VIF) was performed to test for multicollinearity among the predictor variables. A VIF exceeding 10 was regarded as indicating serious multicollinearity, and values greater than 4.0 was considered a cause for concern.27–29 P -values, adjusted odds ratios (ORs) and Wald 95% confidence intervals (CIs) were obtained for the predictor
variables. Furthermore, stratified analysis by CS were also performed. All the statistical analyses were performed using the JMP Pro Ver 14.0 (SAS Institute Inc., Cary, NC, USA). P-values of < 0.05 were considered statistically significant.

Results

A total of 29,599 patients met all inclusion criteria for this study, of whom 12,038 (40.7%) patients were in the GS cohort and 17,561 (59.3%) patients were in non-GS cohorts (Fig. 1). Among the GS cohort, 2,991 (24.8%) patients were in the CS cohort and 9,047 (75.2%) patients were in non-CS cohorts.

The baseline demographics and clinical characteristics of the GS and non-GS cohorts are summarized in Table 2. The mean age was 68 years and 55.6% were male, and most patients had a moderate BMI and a low CCI. In unadjusted comparison, the GS cohort significantly had a higher percentage of patients with age 50–59 or 60–69 (P < 0.0001 each); male (P < 0.0001); normal BMI (P = 0.0313); longer LOS (P < 0.0001); 2 comorbidities at the index admission: diabetes (P = 0.0101) and allergies (P < 0.0001); 11 concomitant drugs at index admission: ischemic heart disease, stroke, diabetes, systemic lupus erythematosus, depression, mental disorders, cancer, allergies, peptic ulcer (P < 0.0001 each), hyperlipidemia (P = 0.0016) and liver insufficiency/failure (P = 0.0294); and a diagnosis of primary open angle glaucoma (POAG) (P < 0.0001) than the non-GS cohort, whereas significantly had a lower percentage of patients with age ≤ 39 or ≥ 80 (P < 0.0001 each); female (P < 0.0001); autumn season admission (P = 0.0041); 1 comorbidity at index admission: hypertension (P = 0.0009): 2 concomitant drugs at index admission: hypertension and heart failure (P < 0.0001 each); and a diagnosis of normal tension glaucoma (NTG) (P < 0.0001). Regarding the primary outcome on the risk factors associated with GS, the 28 variables previously mentioned (see also the Appendix) were included in the initial regression model. Stepwise logistic regression with forward-backward elimination retained 11 of the 20 variables as the significant predictors (P < 0.0001). The VIFs for the predictor variables in this study were all < 4.0, indicating the absence of multicollinearity. Table 3 lists the variables estimated for the final model. The use of cancer drug (adjusted OR: 0.0862, 95% CI: 0.0816–0.0911) and having allergies including systemic and topical (adjusted OR: 0.3590, 95% CI: 0.3223–0.3997) were the most significant predictors of GS, followed by using concomitant drugs including depression, ischemic heart disease and peptic ulcer; being diagnosed with POAG; and longer LOS. In contrast, the use of hypertension drug (adjusted OR: 1.1651, 95% CI: 1.1073–1.2258) and having hypertension (adjusted OR: 1.1621, 95% CI: 1.0640–1.2693) was most strongly associated with reduced likelihood of GS followed by age ≥ 80 and female.

When we restricted the multivariable analysis to the subgroup of patients with GS who had undergone CS, the association between increase CS and baseline characteristics (P < 0.0001); age 70–79 and being diagnosed with POAG were also significant in the model (Table 4).
Table 2
Baseline demographic and clinical characteristics of the study cohorts

| Variable | Glaucoma surgery (N = 12,038) | Non-glaucoma surgery (N = 17,561) | P Value |
|----------|-------------------------------|-----------------------------------|---------|
|          | n | Percentage or mean ± SD | n | Percentage or mean ± SD |         |
| Age (years) | 12038 | 68.5 ± 12.4 | 17561 | 68.8 ± 14.0 | < 0.0001* |
| Category | | | | | |
| ≤ 39 | 305 | 2.5 | 719 | 4.1 | < 0.0001 |
| 40–49 | 628 | 5.2 | 929 | 5.3 | 0.7910 |
| 50–59 | 1488 | 12.4 | 1842 | 10.5 | < 0.0001 |
| 60–69 | 3227 | 26.8 | 4168 | 23.7 | < 0.0001 |
| 70–79 | 4207 | 34.9 | 6069 | 64.6 | 0.4943 |
| ≥ 80 | 2183 | 18.1 | 3034 | 21.8 | < 0.0001 |
| Gender | | | | | |
| Category | | | | | |
| Male | 7032 | 58.4 | 9376 | 53.4 | < 0.0001 |
| Female | 5006 | 41.6 | 8185 | 46.6 | < 0.0001 |
| Body mass index (kg/m²) | 12038 | 22.7 ± 4.3 | 17561 | 22.2 ± 6.2 | < 0.0001* |

AA, α2-agonist; AB, α1-blocker; ABB, αβ-blocker; BB, β-blocker; CAI, carbonic anhydrase inhibitor; Dor, dorzolamide hydrochloride; GE, generic; Lat, latanoprost; NA, not assessed; NTG, normal tension glaucoma; OAG, open angle glaucoma; PG, prostaglandin analog; POAG, primary open angle glaucoma; ROCKI, rho-associated protein kinase inhibitor; SD, standard deviation; Taf, tafluprost; Tim, timolol maleate; Tra, travoprost

*Calculated using the Mann-Whitney U test; the remaining P Values were calculated with the Chi-square test or Fisher’s exact test
| Variable                          | Glaucoma surgery (N = 12,038) | Non-glaucoma surgery (N = 17,561) | P Value |
|----------------------------------|--------------------------------|----------------------------------|---------|
|                                  | n    | Percentage or mean ± SD | n    | Percentage or mean ± SD |                  |
| Category                         |      |                        |      |                        | <0.0001 |
| Thin (< 18.5)                    | 1076 | 8.9                    | 1565 | 8.9                    | 0.9504  |
| Normal (≥ 18.5 < 25)             | 7867 | 65.4                   | 11262| 64.1                   | 0.0313  |
| Fat (≥ 25)                       | 2969 | 24.7                   | 4220 | 24.0                   | 0.2144  |
| Not classified                   | 126  | 1.0                    | 514  | 2.9                    | <0.0001 |
| Smoking index                    | 12038| 91.3 ± 288.5           | 17561| 89.9 ± 290.6           | 0.9622* |
| Maximum                          | 0    |                        | 0    |                        |         |
| Minimum                          | 5000 |                        | 4995 |                        |         |
| Season                           |      |                        |      |                        | 0.0303  |
| Category                         |      |                        |      |                        |         |
| Spring (April-June)              | 3295 | 27.4                   | 4659 | 26.5                   | 0.1093  |
| Summer (July-September)          | 2504 | 20.8                   | 3644 | 20.8                   | 0.9187  |
| Autumn (October-December)        | 2520 | 20.9                   | 3922 | 22.3                   | 0.0041  |
| Winter (January-March)           | 3719 | 30.9                   | 5336 | 30.4                   | 0.3553  |
| Length of stay in hospital       | 12038| 12.1 ± 6.1             | 17561| 8.6 ± 6.0              | <0.0001*|
| Maximum                          | 1    |                        | 1    |                        |         |
| Minimum                          | 99   |                        | 128  |                        |         |

AA, α2-agonist; AB, α1-blocker; ABB, αβ-blocker; BB, β-blocker; CAI, carbonic anhydrase inhibitor; Dor, dorzolamide hydrochloride; GE, generic; Lat, latanoprost; NA, not assessed; NTG, normal tension glaucoma; OAG, open angle glaucoma; PG, prostaglandin analog; POAG, primary open angle glaucoma; ROCKI, rho-associated protein kinase inhibitor; SD, standard deviation; Taf, tafluprost; Tim, timolol maleate; Tra, travoprost

*Calculated using the Mann-Whitney U test; the remaining P Values were calculated with the Chi-square test or Fisher’s exact test
| Variable | Glaucoma surgery (N = 12,038) | Non-glaucoma surgery (N = 17,561) | P Value |
|----------|------------------------------|----------------------------------|---------|
|          | n | Percentage | n | Percentage | n | Percentage |
|          | mean ± SD | mean ± SD |          |          |          |
| Category |   |            |   |            |   |            |
| Low (0)  | 9748 | 81.0 | 14287 | 81.4 | 0.4710 |
| Medium (1–2) | 2177 | 18.1 | 3100 | 17.7 | 0.3457 |
| High (3–4) | 109 | 0.9 | 162 | 0.9 | 0.9013 |
| Very High (≥ 5) | 4 | 0.0 | 12 | 0.1 | 0.3085 |
| Comorbidities | | | | | |
| Circulatory system | | | | | |
| Hypertension | 852 | 7.1 | 1428 | 8.1 | 0.0009 |
| Hypotension | 2 | 0.0 | 5 | 0.0 | 0.7820 |
| Ischemic heart disease | 292 | 2.4 | 412 | 2.3 | 0.6694 |
| Heart failure | 82 | 0.7 | 147 | 0.8 | 0.1377 |
| Stroke | 80 | 0.7 | 118 | 0.7 | 1.0000 |
| Metabolic system | | | | | |
| Diabetes | 1763 | 14.6 | 2386 | 13.6 | 0.0101 |
| Hyperlipidemia | 385 | 3.2 | 575 | 3.3 | 0.7166 |
| Electrolyte disorders | 134 | 1.1 | 232 | 1.3 | 0.1204 |
| Thyroid dysfunction | 14 | 0.1 | 28 | 0.2 | 0.3512 |
| Systemic lupus erythematosus | 10 | 0.1 | 28 | 0.2 | 0.0971 |
| Nervous system | | | | | |

AA, α2-agonist; AB, α1-blocker; ABB, αβ-blocker; BB, β-blocker; CAI, carbonic anhydrase inhibitor; Dor, dorzolamide hydrochloride; GE, generic; Lat, latanoprost; NA, not assessed; NTG, normal tension glaucoma; OAG, open angle glaucoma; PG, prostaglandin analog; POAG, primary open angle glaucoma; ROCKI, rho-associated protein kinase inhibitor; SD, standard deviation; Taf, tafluprost; Tim, timolol maleate; Tra, travoprost

*Calculated using the Mann-Whitney U test; the remaining P Values were calculated with the Chi-square test or Fisher’s exact test
| Variable                  | Glaucoma surgery (N = 12,038) | Non-glaucoma surgery (N = 17,561) | P Value |
|---------------------------|--------------------------------|----------------------------------|---------|
|                           | n                              | Percentage or mean ± SD          | n       | Percentage or mean ± SD |         |
| Dementia                  | 18                             | 0.2                              | 43      | 0.2                     | 0.0894  |
| Depression                | 56                             | 0.5                              | 88      | 0.5                     | 0.7339  |
| Mental disorders          | 1                              | 0.0                              | 0       | 0.0                     | 0.4067  |
| Immune system             |                                |                                  |         |                         |         |
| Cancer                    | 110                            | 0.9                              | 155     | 0.9                     | 0.8017  |
| Allergies                 | 981                            | 8.1                              | 542     | 3.1                     | < 0.0001|
| Gastrointestinal system   |                                |                                  |         |                         |         |
| Peptic ulcer              | 181                            | 1.5                              | 221     | 1.3                     | 0.0821  |
| Liver insufficiency/failure| 30                             | 0.2                              | 35      | 0.2                     | 0.3784  |
| Concomitant drug          |                                |                                  |         |                         |         |
| Circulatory system        |                                |                                  |         |                         |         |
| Hypertension              | 3416                           | 28.4                             | 5546    | 31.6                    | < 0.0001|
| Hypotension               | 36                             | 0.3                              | 56      | 0.3                     | 0.8319  |
| Ischemic heart disease    | 2125                           | 17.7                             | 2625    | 14.9                    | < 0.0001|
| Heart failure             | 3656                           | 30.4                             | 5735    | 32.7                    | < 0.0001|
| Stroke                    | 2942                           | 24.4                             | 3053    | 17.4                    | < 0.0001|

AA, α2-agonist; AB, α1-blocker; ABB, αβ-blocker; BB, β-blocker; CAI, carbonic anhydrase inhibitor; Dor, dorzolamide hydrochloride; GE, generic; Lat, latanoprost; NA, not assessed; NTG, normal tension glaucoma; OAG, open angle glaucoma; PG, prostaglandin analog; POAG, primary open angle glaucoma; ROCKI, rho-associated protein kinase inhibitor; SD, standard deviation; Taf, tafufoprost; Tim, timolol maleate; Tra, travoprost

*Calculated using the Mann-Whitney U test; the remaining P Values were calculated with the Chi-square test or Fisher’s exact test
| Variable                                | Glaucoma surgery (N = 12,038) | Non-glaucoma surgery (N = 17,561) | P Value |
|-----------------------------------------|-------------------------------|----------------------------------|---------|
|                                         | n                             | Percentage or mean ± SD          | n       | Percentage or mean ± SD |
| Diabetes                                | 588                           | 4.9                              | 635     | 3.6                   | < 0.0001 |
| Hyperlipidemia                          | 777                           | 6.5                              | 977     | 5.6                   | 0.0016   |
| Electrolyte disorders                   | 1233                          | 10.2                             | 1907    | 10.9                  | 0.0909   |
| Thyroid dysfunction                     | 78                            | 0.6                              | 106     | 0.6                   | 0.6518   |
| Systemic lupus erythematosus            | 303                           | 2.5                              | 301     | 1.7                   | < 0.0001 |
| Nervous system                          |                               |                                  |         |                       |         |
| Dementia                                | 45                            | 0.4                              | 84      | 0.5                   | 0.2084   |
| Depression                              | 2518                          | 20.9                             | 2005    | 11.4                  | < 0.0001 |
| Mental disorders                        | 2522                          | 21.0                             | 2012    | 11.5                  | < 0.0001 |
| Immune system                           |                               |                                  |         |                       |         |
| Cancer                                  | 9313                          | 77.4                             | 3997    | 22.8                  | < 0.0001 |
| Allergies                               | 436                           | 3.6                              | 433     | 2.5                   | < 0.0001 |
| Gastrointestinal system                 |                               |                                  |         |                       |         |
| Peptic ulcer                            | 336                           | 18.5                             | 2450    | 14.9                  | < 0.0001 |
| Liver insufficiency/failure             | 2230                          | 2.8                              | 418     | 2.4                   | 0.0294   |
| Glaucoma types                          |                               |                                  |         |                       |         |

AA, α2-agonist; AB, α1-blocker; ABB, αβ-blocker; BB, β-blocker; CAI, carbonic anhydrase inhibitor; Dor, dorzolamide hydrochloride; GE, generic; Lat, latanoprost; NA, not assessed; NTG, normal tension glaucoma; OAG, open angle glaucoma; PG, prostaglandin analog; POAG, primary open angle glaucoma; ROCKI, rho-associated protein kinase inhibitor; SD, standard deviation; Taf, tafluprost; Tim, timolol maleate; Tra, travoprost

*Calculated using the Mann-Whitney U test; the remaining P Values were calculated with the Chi-square test or Fisher's exact test
| Variable                        | Glaucoma surgery (N = 12,038) | Non-glaucoma surgery (N = 17,561) | P Value |
|--------------------------------|-------------------------------|----------------------------------|---------|
|                                | n                             | Percentage or mean ± SD          | n       | Percentage or mean ± SD |
| POAG                           | 4404                          | 36.6                             | 5628    | 32.0                   | < 0.0001 |
| OAG                            | 4214                          | 35.0                             | 6300    | 36.0                   | 0.1253   |
| NTG                            | 743                           | 6.2                              | 1331    | 7.6                    | < 0.0001 |
| Not classified                 | 2677                          | 22.2                             | 4320    | 24.5                   | < 0.0001 |
| Glaucoma drug by class         |                               |                                  |         |                        |          |
| PG                             | 2827                          | 23.5                             | 3923    | 22.3                   | 0.0215   |
| BB                             | 713                           | 5.9                              | 1212    | 6.9                    | 0.0008   |
| CAI                            | 1086                          | 9.0                              | 1445    | 8.2                    | 0.0168   |
| ROCKI                          | 694                           | 5.8                              | 928     | 5.3                    | 0.0771   |
| AA                             | 1640                          | 13.3                             | 2317    | 13.2                   | 0.7534   |
| AB                             | 131                           | 1.1                              | 141     | 0.8                    | 0.0130   |
| ABB                            | 14                            | 0.1                              | 17      | 0.1                    | 0.7151   |
| Sympathomimetics               | 12                            | 0.1                              | 11      | 0.1                    | 0.2655   |
| PG/BB fixed combination        | 296                           | 2.5                              | 425     | 2.4                    | 0.8479   |
| CAI/BB fixed combination       | 713                           | 5.9                              | 1212    | 6.9                    | 0.0008   |
| Glaucoma drug by generic name  |                               |                                  |         |                        |          |
| PG                             |                               |                                  |         |                        |          |
| Isopropyl Unoprostone          | 4                             | 0.0                              | 13      | 0.1                    | 0.2165   |

AA, α2-agonist; AB, α1-blocker; ABB, αβ-blocker; BB, β-blocker; CAI, carbonic anhydrase inhibitor; Dor, dorzolamide hydrochloride; GE, generic; Lat, latanoprost; NA, not assessed; NTG, normal tension glaucoma; OAG, open angle glaucoma; PG, prostaglandin analog; POAG, primary open angle glaucoma; ROCKI, rho-associated protein kinase inhibitor; SD, standard deviation; Taf, tafluprost; Tim, timolol maleate; Tra, travoprost

*Calculated using the Mann-Whitney U test; the remaining P Values were calculated with the Chi-square test or Fisher’s exact test
| Variable                  | Glaucoma surgery (N = 12,038) | Non-glaucoma surgery (N = 17,561) | P Value |
|--------------------------|--------------------------------|----------------------------------|---------|
|                          | n | Percentage or mean ± SD | n | Percentage or mean ± SD |         |
| Isopropyl Unoprostone GE | 0 | 0.0 | 0 | 0.0 | NA |
| Latanoprost              | 917 | 7.6 | 1272 | 7.2 | 0.2309 |
| Latanoprost GE           | 152 | 1.3 | 238 | 1.4 | 0.5050 |
| Travoprost               | 377 | 3.1 | 550 | 3.1 | 1.0000 |
| Travoprost GE            | 0 | 0.0 | 0 | 0.0 | NA |
| Tafluprost               | 367 | 3.0 | 669 | 3.8 | 0.0004 |
| Tafluprost GE            | 0 | 0.0 | 0 | 0.0 | NA |
| Bimatoprost              | 1069 | 8.9 | 1274 | 7.3 | < 0.0001 |
| Bimatoprost GE           | 0 | 0.0 | 0 | 0.0 | NA |
| BB Timolol Maleate       | 435 | 3.6 | 761 | 4.3 | 0.0020 |
| Timolol Maleate GE       | 52 | 0.4 | 73 | 0.4 | 0.8544 |
| Carteolol Hydrochloride  | 217 | 1.8 | 367 | 2.1 | 0.0813 |
| Carteolol Hydrochloride GE | 10 | 0.1 | 12 | 0.1 | 0.6687 |
| Betaxolol Hydrochloride  | 2 | 0.0 | 5 | 0.0 | 0.7082 |
| Betaxolol Hydrochloride GE | 0 | 0.0 | 1 | 0.0 | 1.0000 |
| CAI Dorzolamide Hydrochloride | 225 | 1.9 | 295 | 1.7 | 0.2243 |
| Dorzolamide Hydrochloride GE | 0 | 0.0 | 0 | 0.0 | NA |

AA, α2-agonist; AB, α1-blocker; ABB, αβ-blocker; BB, β-blocker; CAI, carbonic anhydrase inhibitor; Dor, dorzolamide hydrochloride; GE, generic; Lat, latanoprost; NA, not assessed; NTG, normal tension glaucoma; OAG, open angle glaucoma; PG, prostaglandin analog; POAG, primary open angle glaucoma; ROCKI, rho-associated protein kinase inhibitor; SD, standard deviation; Taf, tafluprost; Tim, timolol maleate; Tra, travoprost

*Calculated using the Mann-Whitney U test; the remaining P Values were calculated with the Chi-square test or Fisher’s exact test
| Variable          | Glaucoma surgery (N = 12,038) | Non-glaucoma surgery (N = 17,561) | P Value |
|-------------------|-------------------------------|----------------------------------|---------|
|                   | n                             | Percentage or mean ± SD          | n       | Percentage or mean ± SD |         |
| Brinzolamide      | 686                           | 5.7                              | 914     | 5.2                      | 0.0670  |
| Brinzolamide GE   | 0                             | 0.0                              | 0       | 0.0                      | NA      |
| ROCKI             |                               |                                  |         |                          |         |
| Ripasudil Hydrochloride Hydrate | 694 | 5.8 | 928 | 5.3 | 0.0771 |
| Ripasudil Hydrochloride Hydrate GE | 0 | 0.0 | 0 | 0.0 | NA |
| AA                |                               |                                  |         |                          |         |
| Brimonidine Tartrate | 1604 | 13.3 | 2317 | 13.2 | 0.7534 |
| Brimonidine Tartrate GE | 0 | 0.0 | 0 | 0.0 | NA |
| AB                |                               |                                  |         |                          |         |
| Bunazosin Hydrochloride | 131 | 1.1 | 141 | 0.8 | 0.0130 |
| Bunazosin Hydrochloride GE | 0 | 0.0 | 0 | 0.0 | NA |
| ABB               |                               |                                  |         |                          |         |
| Levobunolol Hydrochloride | 2 | 0.0 | 1 | 0.0 | 0.5705 |
| Levobunolol Hydrochloride GE | 0 | 0.0 | 0 | 0.0 | NA |
| Nipradilol        | 13                            | 0.1                              | 16      | 0.1                      | 0.7067  |
| Nipradilol GE     | 0                             | 0.0                              | 1       | 0.0                      | 1.0000  |
| Sympathomimetics  |                               |                                  |         |                          |         |
| Dipivefrin Hydrochloride | 12 | 0.1 | 11 | 0.1 | 0.2917 |
| Dipivefrin Hydrochloride GE | 0 | 0.0 | 0 | 0.0 | NA |

AA, α2-agonist; AB, α1-blocker; ABB, αβ-blocker; BB, β-blocker; CAI, carbonic anhydrase inhibitor; Dor, dorzolamide hydrochloride; GE, generic; Lat, latanoprost; NA, not assessed; NTG, normal tension glaucoma; OAG, open angle glaucoma; PG, prostaglandin analog; POAG, primary open angle glaucoma; ROCKI, rho-associated protein kinase inhibitor; SD, standard deviation; Taf, tafluprost; Tim, timolol maleate; Tra, travoprost

*Calculated using the Mann-Whitney U test; the remaining P Values were calculated with the Chi-square test or Fisher's exact test
| Variable                  | Glaucoma surgery (N = 12,038) | Non-glaucoma surgery (N = 17,561) | P Value |
|--------------------------|--------------------------------|----------------------------------|---------|
|                          | n                              | Percentage or mean ± SD          | n       | Percentage or mean ± SD |         |
| PG/BB fixed combination  |                                |                                  |         |                         |         |
| Lat/Tim                  | 114                            | 0.9                              | 211     | 1.2                     | 0.0409  |
| Lat/Tim GE               | 0                              | 0.0                              | 0       | 0.0                     | NA      |
| Lat/Car                  | 1                              | 0.0                              | 3       | 0.0                     | 0.6560  |
| Lat/Car GE               | 0                              | 0.0                              | 0       | 0.0                     | NA      |
| Tra/Tim                  | 141                            | 1.2                              | 163     | 0.9                     | 0.0459  |
| Tra/Tim GE               | 0                              | 0.0                              | 0       | 0.0                     | NA      |
| Taf/Tim                  | 41                             | 0.3                              | 51      | 0.3                     | 0.4582  |
| Taf/Tim GE               | 0                              | 0.0                              | 0       | 0.0                     | NA      |
| CAI/BB fixed combination |                                |                                  |         |                         |         |
| Dor/Tim                  | 1519                           | 12.6                             | 2327    | 13.3                    | 0.1133  |
| Dor/Tim GE               | 0                              | 0.0                              | 0       | 0.0                     | NA      |
| Brinzolamide/Tim         | 359                            | 3.0                              | 547     | 3.1                     | 0.5364  |
| Brinzolamide/Tim GE      | 0                              | 0.0                              | 0       | 0.0                     | NA      |

AA, α2-agonist; AB, α1-blocker; ABB, αβ-blocker; BB, β-blocker; CAI, carbonic anhydrase inhibitor; Dor, dorzolamide hydrochloride; GE, generic; Lat, latanoprost; NA, not assessed; NTG, normal tension glaucoma; OAG, open angle glaucoma; POAG, primary open angle glaucoma; ROCKI, rho-associated protein kinase inhibitor; SD, standard deviation; Taf, tafluprost; Tim, timolol maleate; Tra, travoprost

*Calculated using the Mann-Whitney U test; the remaining P Values were calculated with the Chi-square test or Fisher's exact test
Table 3
Logistic regression analysis of factors associated with or without glaucoma surgery

| Variable              | Estimate | Adjusted OR (95% CI)          | P Value |
|-----------------------|----------|-------------------------------|---------|
| Hypertension drug     | 0.649155 | 1.1651(1.1073–1.2258)         | < 0.0001|
| Hypertension          | 0.33362 | 1.1621(1.0640–1.2693)         | < 0.0001|
| Age ≥ 80              | 0.174507 | 1.2609(1.0189–1.3370)         | < 0.0001|
| Female                | 0.151442 | 1.2263(1.1702–1.2851)         | < 0.0001|
| Length of stay in hospital | -0.06979 | 0.8942 (0.8899–0.8984)       | < 0.0001|
| POAG                  | -0.17228 | 0.8175(0.7789–0.8584)         | < 0.0001|
| Peptic ulcer drug     | -0.27303 | 0.7131(0.6697–0.7593)         | < 0.0001|
| Ischemic heart disease drug | -0.29949 | 0.8199(0.7701–0.8728)       | < 0.0001|
| Depression drug       | -0.4121  | 0.4873(0.4571–0.5195)         | < 0.0001|
| Allergies             | -0.57812 | 0.3590(0.3223–0.3997)         | < 0.0001|
| Cancer drug           | -2.23632 | 0.0862(0.0816–0.0911)         | < 0.0001|

CI, confidence interval; OR, odd ratio; POAG, primary open angle glaucoma

Table 4
Logistic regression analysis of factors associated with or without combined glaucoma and cataract surgery

| Variable              | Estimate | Adjusted OR (95% CI)          | P Value |
|-----------------------|----------|-------------------------------|---------|
| Age ≤ 39              | 2.62523  | 1.2066(6.2634–25.5751)        | < 0.0001|
| Age 40–49             | 1.603633 | 4.7396(3.4675–6.4783)         | < 0.0001|
| Age 50–59             | 0.965275 | 2.6394(2.2454–3.1026)         | < 0.0001|
| Cancer drug           | 0.384652 | 1.4361(1.3062–1.5789)         | < 0.0001|
| Hyperlipidemia drug   | 0.194787 | 1.2737(1.0657–1.5222)         | < 0.0001|
| POAG                  | -0.17353 | 0.8450(0.7761–0.9199)         | < 0.0001|
| Age 70–79             | -0.28579 | 0.5642(0.5184–0.6140)         | < 0.0001|

CI, confidence interval; OR, odd ratio; POAG, primary open angle glaucoma

The rate of comorbidities and the rate of concomitant use of prescribed systemic oral drugs in the GS and non-GS cohorts are shown in Fig. 2. The most common comorbidity was diabetes in both, the GS (14.6%) and non-GS cohort (13.6%). Diabetes was followed by allergy, hypertension, hyperlipidemia and
Ischemic heart disease. Allergy was remarkably higher in the GS cohort (Fig. 2A). Concomitant drugs use with frequency > 10% and significant difference in the two cohorts were hypertension, Ischemic heart disease, heart failure, stroke, depression, mental disorders, cancer and peptic ulcer. The use of cancer drug was remarkably higher in the GS cohort. (Fig. 2B). Among the GS cohort, the rate of comorbidities and the rate of concomitant use of prescribed systemic oral drugs in the CS and non-CS cohorts are shown in Fig. 3. The most common comorbidity was diabetes in both, the CS (17.7%) and non-CS cohort (19.3%). Diabetes was followed by allergy and hypertension; however, the lack of significant differences was shown between the two cohorts (Fig. 3A). Concomitant drugs use with frequency > 10% and significant difference in the two cohorts were depression, mental disorders, and cancer (Fig. 3B).

The treatment patterns of prescribed topical glaucoma drugs (eye drops) at the index admission are summarized in Fig. 4 and Fig. 5. In the GS cohort, PG accounted for one third of total glaucoma eye drops. PG [2827 (23.5%)] was followed by AA [1640 (13.3%), CAI [1086 (9.0%)] and BB [713 (5.9%)] by drug class; the most commonly used as first-line treatment was bimatoprost (8.9%) followed by latanoprost (7.6%), travoprost (3.1%) and tafluprost (3.0%) by generic name, including only original drugs not generic drugs (Fig. 4A). In the non-GS cohort, which has the similar treatment pattern to the GS cohort, PG [3923 (22.3%), AA [2317 (13.2%)], CAI [1445 (8.2%)] and BB [1212 (6.9%)] were used by drug class, and the most commonly used as first-line treatment was bimatoprost (7.3%), followed by latanoprost (7.2%), tafluprost (3.8%) and travoprost (3.1%) by generic name (Fig. 4B). In the CS cohort, PG accounted for one third of total glaucoma eye drops. PG [673 (29.2%)] was followed by AA [372 (16.2%), CAI [301 (13.1%)] and BB [203 (8.8%)] by drug class; the most commonly used as first-line treatment was latanoprost (10.2%), followed by bimatoprost (9.3%), travoprost (4.4%) and tafluprost (4.1%) by generic name (Fig. 5A). In the non-CS cohort, which has the similar treatment pattern to the CS cohort, PG [2154 (30.7%), AA [1232 (17.6%)], CAI [785 (11.2%)] and ROCK [557 (7.9%)]] were used by drug class, and the most commonly used as first-line treatment was bimatoprost (12.2%), followed by latanoprost (9.7%), travoprost (3.9%) and tafluprost (3.9%) by generic name (Fig. 5B).

**Discussion**

To date, we found no other studies that identified the risk factors associates with GS in patients with glaucoma in Japan or other countries. Our study did and revealed a significant influence of 11 variables on GS extracted from the claims database. Of these, 7 were significant more likely to increase GS, and 4 were significant more likely to decrease GS. The immune-related comorbidities and concomitant drugs use were the most likely to be GS. Although there was no difference in the treatment pattern of prescribed glaucoma eye drops between the GS cohort and the non-GS cohort, the rate of the comorbidities and the rate of concomitant drugs use were similar trend to the above identified variables. Therefore, careful management of glaucoma patients with these variables may be important factor for reducing glaucoma surgery burden.

In Japan, TLO is also often preferred as GS, and TRAB may target relatively sever glaucoma patients. Since this study used DPC data collected form patients who were admitted to the nationwide acute care...
hospitals, we assumed that patients with relatively severe glaucoma were included and considered appropriate to select only TRAB as GS. On the other hand, since TLO such as microhook TLO is often additionally used during CS, it is difficult to be an indicator for estimating exacerbation risk of glaucoma.

Among the 17 disease as the possible risk factors for glaucoma\(^2\) (see *Variable* in the Method section), allergies were identified as the risk factors of comorbidities leading to GS. Our finding might be explained by the previous studies: the toll-like receptor 4 (TLR4), a transmembrane receptor that mediates immune responses to exogenous, is associated with the risk of NTG.\(^3\) The microglia are related to the immunocompetent cells of the central nervous system, and microglial activation has been reported in glaucoma,\(^4\) which might contribute to a higher prevalence of immune-related comorbidities such as allergies.

Among systemic oral drugs for the 17 disease, cancer, depression, ischemic heart disease or peptic ulcer were identified as the risk factors of concomitant drugs leading to GS. According to the previous studies, the downregulation of cell cycle progression by checkpoint inhibitors has recently been targeting for cancer therapy,\(^5\) \(^6\) can cause cell death beyond cancer cells, and therefore may induce neurodegenerative disorders such as glaucoma.\(^7\) However, one of the risk factors for glaucoma is increased oxidative stress, and drugs targeting oxidative stress in cancer could reduce the oxidative stress-induced apoptosis of retinal ganglion cells in glaucoma.\(^8\)\(^9\) Therefore, we have not been able to identify reports from previous studies of whether cancer drugs is associated with GS. Other studies report that depression is strongly linked with glaucoma and results in elevated oxidative stress.\(^10\) Likewise, ischemic heart disease is linked with glaucoma probably affect vasculature dysfunction.\(^11\) Furthermore, many factors contribute to peptic ulcer including glaucoma is another likely reason that may contribute to the positive association. In contrast, hypertension and its drug were identified as the risk factors leading to non-GS. Our finding might to be in line with the previous studies that hypertension improve ocular blood flow,\(^12\) however, hypertension oral administration is a risk of glaucoma progression.\(^13\) Stratified analysis based in CS showed that none of the 17 disease were identified as the risk factors leading to CS combined with GS.

In addition, patients with POAG was also identified as the significant more likely to be GS. The rate for glaucoma type in subjects 40 years of age and older was estimated at 5.0% for all glaucoma, 0.3% for POAG, and 3.6% for NTG.\(^14\) In contrast, this study showed that the rates of POAG, OAG and NTG at the index admission were 36.6%, 35.0% and 6.2%, respectively, in the GS cohort, and 32.0%, 36.0% and 7.6%, respectively, in the non-GS cohort. The ratios of NTG seem to be fewer than expected. One possible explanation could be that the rate of progress of glaucomatous optic neuropathy among patients with NTG is generally slower than that among those with other types of glaucoma, therefore, patients with NTG have less need to go to DPC hospitals.

Furthermore, this study identified longer LOS as the factors associate with GS. Japanese hospitals generally provide rehabilitation and nursing care in addition to acute medical care, which may contribute
to the longer LOS.

Patients in both cohorts, the high rate of comorbidities and concomitant drugs use were similar trend to the above identified variables. In the GS cohort, allergy and cancer drugs were most significantly higher than the non-GS cohort. Diabetes was the most common comorbidities in both, the GS (14.6%) and non-GS cohort (13.6%), and significantly higher in the GS cohorts, but not identified as the risk factors leading to GS. On the other hand, the rate of the diabetes drug use was low in both, the GS (4.9%) and non-GS cohort (3.6%). Patients with glaucoma who had diabetes may be able to handle with drug treatment without surgical treatment.

The treatment patterns of prescribed glaucoma eye drops at the index admission was similar between the two cohorts; PG was most commonly prescribed, AA and CAI were second and third, respectively. Our result is in line with the data from a published report indicating that the most commonly used first-line monotherapy was a PG,\textsuperscript{43–46} while CAI/BB was the most commonly used fixed combination as first- and second-line treatment.\textsuperscript{47,48} Although BB is also recommended as a first-line monotherapy in the guideline for glaucoma, the prescription rate of BB was low in this study. This is probably because the patients had comorbidities of asthmas, chronic obstructive pulmonary disease or heart failure may not prescribed BB according to the respective drug information. Or elderly patients may have difficult using BB. On the other hand, BB was considered to be common in the GS cohorts because of bradycardia, but not so in our results. The ROCKI as well as the EP2 receptor agonist become available in Japan recently and has been reported to show an additional IOP-lowering in combination with other glaucoma ophthalmic solutions.\textsuperscript{49–52} Thus, the prescription trend for glaucoma eye drops may change in the future.

This study had several limitations. First, we included only DPC hospitals with glaucoma beds, so the results may not be generalizable; however, DPC database contains detailed medical data on numerous patients residing throughout the Japan in a broad array of geographic regions. Moreover, the variables included in the final predictive model are available in other Japanese administrative claims databases. Second, limitations common to studies using administrative claims data apply to this study.\textsuperscript{53–56} These limitations include lack of certain information in the database and errors or omissions in claims coding. Third, claims data lack clinical information (such as IOP, visual field, etc.) to access disease severity. Therefore, it was not possible to evaluate whether the severity level of documented comorbid conditions was comparable between our study cohorts and whether different stages of glaucoma were associated with specific comorbidity profiles. Fourth, our data did not exclude laser trabeculoplasty (LT). Although, LT reported to be an alternative to topical glaucoma drug treatment and the same IOP-lowering effect as eye drops as monotherapy,\textsuperscript{57} it may have influenced the results of our analysis. Fifth, unmeasured confounders may limit the findings. Finally, the present analyses were built according to the assumption that all the claimed drugs were used by the patients. To address these limitations, we need to conduct further studies using the real-world data combined with clinical data.

Conclusions
The results of this study show that the risk factors leading to GS of glaucoma patient can be predicted with 7 commonly available demographic and administrative claim-based variables including: having comorbidities related to allergies; taking concomitant drugs related to cancer, depression, ischemic heart disease and peptic ulcer; being diagnosed with POAG, and longer LOS. Furthermore, the rate of comorbidities and the rate of concomitant drug use were similar tendency as the above identified variables. Therefore, before starting glaucoma treatment, special focus on Japanese patients with glaucoma, especially POAG, who have allergy-related comorbidities, or take the immune, nervous, circulatory or gastrointestinal system-related concomitant drugs, through medical interview by ophthalmologists seems to be desirable.

**Abbreviations**

AA: α2 agonist; AB: α1 blocker; ABB: αβ blocker; BB: β blocker; BMI: body mass index; CAI: carbonic anhydrase inhibitor; CCI: charlson comorbidity index; CIs: confidence intervals; CS: cataract surgery; DPC: diagnosis procedure combination; GS: glaucoma surgery; ICD: international statistical classification of disease; IOP: intraocular pressure; LOS: length of stay in hospital; LT: laser trabeculoplasty; NTG, normal tension glaucoma; OAG, open angle glaucoma; OR: odds ratio; PG: prostaglandin analog; POAG, primary open angle glaucoma; ROCKI: rho-associated coiled kinase inhibitor; SD: standard deviation; TLO: trabeculotomy; TRAB: trabeculectomy; VIF: variance inflation factor.

**Declarations**

**Ethics approval and consent to participate**

This study was conducted in accordance with the Declaration of Helsinki and was approved by the research ethics committee of the Tohoku University Graduate School of Medicine, Japan (No. 2019-1-897). This study acquired secondary data from a medical claims database, written informed consent from patients was not required.

**Consent for publication**

Not applicable.

**Availability of data and materials**

The data that support the findings of this study are available from the DPC Study Group, a government-funded academic group, but restrictions apply to the availability of these data, which were used under license for the current study. Therefore, the data are not publicly available. The data are however available from the authors upon reasonable request and with the permission of the DPC Study Group.

**Competing interests**

The authors declare that they have no competing interests.
Funding

Not applicable.

Authors' contributions

CS, ST, KF and TN were involved in the conceptual development and study design. KF and KF developed the database and CS, KT and KF performed the statistical analysis. All authors participated in the interpretation of data and in drafting and/or revising the manuscript critically for developing important intellectual content. All authors read and approved the final manuscript.

Acknowledgments

This study was supported by a Grant-in-Aid for Research on Policy Planning and Evaluation from the Ministry of Health, Labour and Welfare, Japan.

Author details

1 Department of Ophthalmology, Tohoku University Graduate School of Medicine, Sendai, Japan
2 Department of Health Administration and Policy, Tohoku University Graduate School of Medicine, Sendai, Japan
3 Department of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School of Medicine, Tokyo, Japan

References

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006; 90:262-267.
2. Parihar JKS. Glaucoma: The 'Black hole' of irreversible blindness. Med J Armed Forces India. 2016; 72:3-4.
3. Nordstrom BL, Friedman DS, Mozaffari E, Quigley HA, Walker AM. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol. 2005; 140:598-606
4. Garway-Heath DF, Crabb DP, Bunce C. et al, Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet. 2015; 385:1295-304.
5. The Japan Glaucoma Society Guidelines for Glaucoma (4th Edition). Nippon Ganka Gakkai Zasshi. 2018; 122:5-53. http://www.nichigan.or.jp/member/guideline/glaucoma4.pdf. Last accessed on November 8, 2020. (in Japanese).
6. Morizane Y, Morimoto N, Fujiwara A. et al. Incidence and causes of visual impairment in Japan: the first nation-wide complete enumeration survey of newly certified visually impaired individuals. Jpn J Ophthalmol. 2019; 63:26-33.
7. Iwase A, Suzuki Y, Araie M. et al. The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. 2004; 111:1641-1648
8. Coleman AL, Miglior S. Risk factors for glaucoma onset and progression, Surv Ophthalmol. 2008; 53:3-10
9. Tham YC, Li X, Wong TY. et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014; 121:2081-2090.
10. Richter GM, Coleman AL. Minimally invasive glaucoma surgery: current status and future prospects. Clinical Ophthalmology. 2016; 10:189–206.
11. Bovee CE, Pasquale LR. Evolving surgical interventions in the treatment of glaucoma. Seminars in Ophthalmology. 2017; 32: 91–95.
12. Chen DZ, Sng CCA. Safety and efficacy of microinvasive glaucoma surgery. Journal of Ophthalmology. 2017; Article ID 3182935:13.
13. Masuda S. Casemix as a tool for transparency of medical service. The Japanese Journal of Security Policy. 2007; 6:43-53
14. Fushimi K, Hashimoto H, Imanaka Y. et al. Functional mapping of hospitals by diagnosis-dominant case-mix analysis. BMC Health Serv Res 2007; 7:50
15. Matsuda S. Case mix as a tool for transparency of medical services. The Japanese Journal of Security Policy. 2017; 6:11.
16. Yasuda S, Nakao K, Nishimura K. et al. The current status of cardiovascular medicine in Japan: Analysis of a large number of health records from a nationwide claim-based database, JROAD-DPC. Circ J. 2016; 80:2327-2335.
17. Yasunaga H, Ide H, Imamura T, Ohe K. Impact of the Japanese diagnosis procedure combination-based payment system on cardiovascular medicine-related costs. Int Heart J 2005; 46: 855-866.
18. Nakamura K. Diagnosis procedure combination database would develop nationwide clinical research in Japan. Circ J 2016; 80: 2289-2290.
19. Tarasawa K, Fujimori K, Fushimi K. Recombinant Human Soluble Thrombomodulin Contributes to a Reduction In-Hospital Mortality of Acute Cholangitis with Disseminated Intravascular Coagulation: A Propensity Score Analyses of a Japanese Nationwide Database. Tohoku J Exp Med. 2020; 252:53-61
20. Iihara K, Nishimura K, Kada A. et al. The impact of comprehensive stroke care capacity on the hospital volume of stroke interventions: A nationwide study in Japan: J-ASPECT study. J Stroke Cerebrovasc Dis. 2014; 23:1001-1018.
21. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40:373-383.
22. Sundararajan V, Quan H, Halfon P. et al. Cross-national comparative performance of three versions of the ICD-10 Charlson index. Med Care. 2007; 45:1210-1215.
23. Ho H, Shi Y, Chua J. et al. Association of Systemic Medication Use With Intraocular Pressure in a Multiethnic Asian Population: The Singapore Epidemiology of Eye Diseases Study. JAMA
24. Chen VC, Ng M, Chiu W. et al. Effects of selective serotonin reuptake inhibitors on glaucoma: A nationwide population-based study. *PLoS One.* 2017; 12:e0173005.
25. Chen HY, Hsu SY, Chang YC. et al. Association Between Statin Use and Open-angle Glaucoma in Hyperlipidemia Patients: A Taiwanese Population-based Case-control Study. *Medicine (Baltimore).* 2015; 94:e2018
26. Shiga Y, Akiyama M, Nishiguchi KM. et al. Genome-wide association study identifies seven novel susceptibility loci for primary open-angle glaucoma. *Hum Mol Genet.* 2018; 27:1486-1496
27. Gueugnon M, Stapley PJ, Gouteron A. et al. Age-Related Adaptations of Lower Limb Intersegmental Coordination During Walking. *Front Bioeng Biotechnol.* 2019; 7:173
28. Aizawa H, Imai S, Fushimi K. Factors associated with 30-day readmission of patients with heart failure from a Japanese administrative database. *BMC Cardiovasc Disord.* 2015; 15:134.
29. Hayashi T, Boyko EJ, Leonetti DL. et al. Visceral adiposity is an independent predictor of incident hypertension in Japanese Americans. *Ann Intern Med.* 2004; 140:992-1000.
30. Shibuya E, Meguro A, Ota M. et al. Association of Toll-like receptor 4 gene polymorphisms with normal tension glaucoma. *Invest Ophthalmol Vis Sci.* 2008; 49:4453-4457.
31. Ramirez AI, de Hoz R, Salobrar-Garcia E. et al. The Role of Microglia in Retinal Neurodegeneration: Alzheimer's Disease, Parkinson, and Glaucoma. *Front Aging Neurosci.* 2017; 9:1-21.
32. Visconti R, Monica RD, Grieco D. Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword. *J Exp Clin Cancer Res.* 2016; 35: 153.
33. Benada J, Macurek L. Targeting the Checkpoint to Kill Cancer Cells. *Biomolecules.* 2015; 5: 1912-1937.
34. Golubnitschaja O. Cell cycle checkpoints: the role and evaluation for early diagnosis of senescence, cardiovascular, cancer, and neurodegenerative diseases. *Amino Acids.* 2007;32:359-3571.
35. Kimura A, Namekata N, Guo X. et al. Targeting Oxidative Stress for Treatment of Glaucoma and Optic Neuritis. *Oxid Med Cell Longev.* 2017; 2817252.
36. Wang C, Ren YL, Zhai J. et al. Down-regulated LAMA4 inhibits oxidative stress-induced apoptosis of retinal ganglion cells through the MAPK signaling pathway in rats with glaucoma. *Cell Cycle.* 2019 May;18:932-948.
37. Chen YY, Lai YJ, Wang JP. et al. The association between glaucoma and risk of depression: a nationwide population-based cohort study. *BMC Ophthalmol.* 2018; 18: 146
38. Gislaine Z, Réus AS, Carlessi RH. et al. Relationship of Oxidative Stress as a Link between Diabetes Mellitus and Major Depressive Disorder. *Oxid Med Cell Longev.* 2019; e8637970.
39. Chen YY, Hu HY, Chu D. et al. Patients with Primary Open-Angle Glaucoma May Develop Ischemic Heart Disease More Often than Those without Glaucoma: An 11-Year Population-Based Cohort Study. *PLoS One.* 2016; 11: e0163210.
40. Knox DL. Glaucomatocyclitic crises and systemic disease: peptic ulcer, other gastrointestinal disorders, allergy and stress. *Trans Am Ophthalmol Soc.* 1988;86:473-495.

41. Caprioli J, Coleman AL. Blood Flow in Glaucoma Discussion; Blood pressure, perfusion pressure, and glaucoma. *Am J Ophthalmol.* 2010;149:704-712.

42. Krupin T, Liebmann JM, Greenfield DS. et al. Low-Pressure Glaucoma Study Group. The Low-pressure Glaucoma Treatment Study (LoGTS) study design and baseline characteristics of enrolled patients. 2005;112:376-385.

43. Choudhari NS, Pathak-ray V, Kaushik S, Vyas P, George R. Understanding practice patterns of glaucoma sub-specialists in India. *Int J Ophthalmol.* 2017; 10:1580-1585.

44. Coleman AL, Lum FC, Su Z, Gliklich RE. Practice patterns and treatment changes for open-angle glaucoma: the RiGOR study. *J Comp Eff Res.* 2016; 5:79-85.

45. Marquis RE, Whitson JT. Management of glaucoma: focus on pharmacological therapy. *Drugs Aging.* 2005; 22:1-21.

46. Whitson JT. Glaucoma: a review of adjunctive therapy and new management strategies. *Expert Opin Pharmacother.* 2007; 8:39-40

47. Goldshtein I, Shalev V, Zigman N. The Maccabi glaucoma study: treatment patterns and persistence with glaucoma therapy in a large Israeli health maintenance organization. *J Glaucoma.* 2016; 25:386–3891.

48. Kim CY, Park KH, Ahn J. et al. Treatment patterns and medication adherence of patients with glaucoma in South Korea. *Br J Ophthalmol.* 2017; 101:801-807.

49. Tanihara H, Inoue T, Yamamoto T. et al. Additive intraocular pressure-lowering effects of the rho kinase inhibitor ripasudil (K-115) combined with timolol or latanoprost: a report of 2 randomized clinical trials. *JAMA Ophthalmology.* 2015; 133:755-761.

50. Yamamoto K, Maruyama K, Himori, N. et al. The novel rho kinase (ROCK) inhibitor K-115: a new candidate drug for neuroprotective treatment in glaucoma. *Investigative Ophthalmology.* 2014; 55:7126-7136.

51. Iwamura R, Tanaka M, Okanari E. et al. Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl. *J Med Chem.* 2018; 61:6869-6891.

52. Aihara M, Lu F, Kawata, H. et al. Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension. *J Glaucoma.* 2019; 28:375-385.

53. Grimes D. Epidemiologic research using administrative databases: garbage in, garbage out. *Obstet Gynecol.* 2010; 116:1018-1019.

54. Hennessy S. Use of health care databases in pharmacoepidemiology. *Basic Clin Pharmacol Toxicol.* 2006; 98:311-313.
55. Hersh WR, Weiner MG, Embi PJ. et al. Caveats for the use of operational electronic health record data in comparative effectiveness research. *Med Care.* 2013; 51: 30-37.

56. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. *J Clin Epidemiol.* 2005; 58:323-337.

57. Gazzard G, Konstantakopoulou E, Garway-Heath D. et al., LiGHT Trial Study Group. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. 2019; 393:1505-1516.